BARCLAYS PLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 50 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$1,950,000
+1641.1%
2,629,000
+1805.1%
0.00%
Q1 2020$112,000
-86.1%
138,000
-85.3%
0.00%
-100.0%
Q3 2019$805,000
+509.8%
936,000
+532.4%
0.00%
Q2 2019$132,000
+2100.0%
148,000
+2014.3%
0.00%
Q4 2018$6,000
-97.3%
7,000
-97.6%
0.00%
Q3 2017$226,000293,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2020
NameSharesValueWeighting ↓
SILVERBACK ASSET MANAGEMENT LLC 12,851,000$12,016,0002.95%
Context Capital Management, LLC 3,000,000$2,804,0002.24%
Man Investments (CH) AG 3,000,000$2,798,0001.76%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 42,500,000$39,540,0001.52%
MACKAY SHIELDS LLC 17,069,000$15,982,0000.73%
HIGHFIELDS CAPITAL MANAGEMENT LP 73,035,000$68,425,0000.63%
WOLVERINE ASSET MANAGEMENT LLC 42,307,000$39,554,0000.61%
LINDEN ADVISORS LP 14,122,000$13,194,0000.49%
GLG LLC 9,100,000$8,486,0000.47%
Jabre Capital Partners S.A. 3,400,000$3,179,0000.38%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders